Detalles de la búsqueda
1.
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
N Engl J Med
; 379(8): 753-763, 2018 08 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-30110579
2.
PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy.
Breast Cancer Res Treat
; 177(3): 659-667, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31297647
3.
Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).
BMC Cancer
; 18(1): 1127, 2018 Nov 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-30445935
4.
The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
BMC Cancer
; 18(1): 526, 2018 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29728098
5.
Evaluation of the Theoretical Teaching of Postgraduate Radiation Oncology Medical Residents in France: a Cross-Sectional Study.
J Cancer Educ
; 33(2): 383-390, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28138918
6.
SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.
Breast Cancer Res Treat
; 154(2): 351-7, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26536871
7.
Neurotoxicity as a prognostic factor in patients with metastatic breast cancer treated with ixabepilone as a first-line therapy.
Oncology
; 88(3): 180-8, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25472499
8.
Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial.
Future Oncol
; 11(16): 2283-97, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26260807
9.
Chemotherapy-Related Reticulate Hyperpigmentation: A Case Series and Review of the Literature.
Dermatology
; 231(4): 312-8, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26422424
10.
Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
Breast Cancer Res
; 16(6): 466, 2014 Nov 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-25416589
11.
Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series.
Breast Cancer Res Treat
; 146(2): 451-6, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24929675
12.
Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial.
Breast Cancer Res Treat
; 139(3): 789-800, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23780683
13.
DNA polymerase theta up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability.
Proc Natl Acad Sci U S A
; 107(30): 13390-5, 2010 Jul 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-20624954
14.
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.
Lancet Oncol
; 13(4): 375-84, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22377126
15.
Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer.
Cancer
; 118(2): 461-8, 2012 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21598243
16.
Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.
Oncologist
; 17(7): 900-9, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22610153
17.
Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials.
Support Care Cancer
; 20(11): 2661-8, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22382588
18.
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Lancet Oncol
; 12(4): 369-76, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21429799
19.
Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer.
Clin Cancer Res
; 28(7): 1383-1390, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35091441
20.
Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial.
Breast Cancer Res
; 13(6): R109, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-22044691